Aurinia Pharmaceuticals vs Xeris Biopharma
Xeris Biopharma reported revenue of $292 million in fiscal 2025, about the same as Aurinia Pharmaceuticals' $283 million in fiscal 2025. Aurinia Pharmaceuticals' revenue grew 20.4% in its latest year, and Xeris Biopharma's grew 43.7%. Aurinia Pharmaceuticals had an operating margin of 37.1%, against 8.5% at Xeris Biopharma.
Side by side
| Aurinia Pharmaceuticals | Xeris Biopharma | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $283M | $292M |
| Revenue growth | 20.4% | 43.7% |
| Revenue growth a year, last 5 years | 41.4% | 70.3% |
| Gross margin | 88.5% | — |
| Operating margin | 37.1% | 8.5% |
| Net margin | 101.5% | 0.2% |
| Free cash flow | $135M | — |
| Free cash flow margin | 47.8% | — |
| Return on capital | — | 19.6% |
| Net debt to EBITDA | — | 4.2x |
| Dividends and buybacks | $98M | $0M |
| Change in diluted share count | −5.1% | 17.7% |
| Last close | $15.73 | $16.66 |
| P/E at the last close | 6.9× | — |
| Insider trades, last 12 months | bought $25.1 million, sold $546,373 | sold $4.7 million |
| Piotroski F-score | — | 7 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aurinia PharmaceuticalsXeris Biopharma
Operating margin
Percent of revenue
Aurinia PharmaceuticalsXeris Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aurinia PharmaceuticalsXeris Biopharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aurinia Pharmaceuticals and Xeris Biopharma pages.